Search

GlaxoSmithKline PLC

Fermé

SecteurSoins de santé

1,888 -1.44

Résumé

Variation du prix de l'action

24h

Actuel

Min

1887.5

Max

1899.5

Chiffres clés

By Trading Economics

Revenu

1.2B

1.8B

Ventes

-989M

7.6B

P/E

Moyenne du Secteur

13.597

50.102

BPA

0.465

Rendement du dividende

3.5

Marge bénéficiaire

24.105

Employés

66,841

EBITDA

577M

2.8B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+10.68% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.50%

2.33%

Prochains Résultats

28 juil. 2026

Date du Prochain Dividende

9 juil. 2026

Date du Prochain Détachement de Dividende

13 août 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-3B

77B

Ouverture précédente

1889.44

Clôture précédente

1888

Sentiment de l'Actualité

By Acuity

46%

54%

121 / 344 Classement par Healthcare

GlaxoSmithKline PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 avr. 2026, 06:42 UTC

Résultats

GSK Earnings Boosted by Higher Specialty Medicine Sales

29 mai 2026, 09:17 UTC

Market Talk

GSK Hepatitis B Drug Data Beat Expectations -- Market Talk

6 mai 2026, 13:35 UTC

Market Talk

GSK Is Taking Steps in Right Direction, But Might Need More -- Market Talk

29 avr. 2026, 10:39 UTC

Market Talk
Acquisitions, Fusions, Rachats

GSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk

29 avr. 2026, 10:06 UTC

Market Talk
Résultats

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

29 avr. 2026, 10:02 UTC

Market Talk
Résultats

GSK Makes Ideal Start for New CEO -- Market Talk

29 avr. 2026, 06:07 UTC

Résultats

GSK PLC Sees 70p 2026 Dividend Payout

29 avr. 2026, 06:07 UTC

Résultats

GSK PLC Declares Dividend of 17p

29 avr. 2026, 06:07 UTC

Résultats

GSK PLC Free Cash Flow of GBP0.8B

29 avr. 2026, 06:06 UTC

Résultats

GSK PLC Cash Generated From Operations GBP1.4B

29 avr. 2026, 06:06 UTC

Résultats

GSK PLC 1Q General Medicines Sales GBP2.3B

29 avr. 2026, 06:06 UTC

Résultats

GSK PLC 1Q Vaccines Sales GBP2.1B

29 avr. 2026, 06:06 UTC

Résultats

GSK PLC 1Q Specialty Medicines Sales GBP3.2B

29 avr. 2026, 06:05 UTC

Résultats

Analysts Saw GSK PLC 1Q Net Profit at GBP1.74B

29 avr. 2026, 06:04 UTC

Résultats

Analysts Saw GSK 1Q Adjusted Operating Profit of GBP2.46B

29 avr. 2026, 06:04 UTC

Résultats

GSK PLC 1Q Adjusted Operating Profit GBP2.65B

29 avr. 2026, 06:04 UTC

Résultats

Analysts Saw GSK PLC Core EPS of 43.3p

29 avr. 2026, 06:04 UTC

Résultats

Analysts Saw GSK PLC 1Q Turnover at GBP7.58B

29 avr. 2026, 06:04 UTC

Résultats

GSK PLC 1Q Adj EPS 46.50p

29 avr. 2026, 06:01 UTC

Résultats

GSK PLC Sees 2026 Adjusted EPS Growth of 7%-9%

29 avr. 2026, 06:01 UTC

Résultats

GSK PLC Sees 2026 Adjusted Oper Pft Growth of 7%-9%

29 avr. 2026, 06:01 UTC

Résultats

GSK PLC Sees 2026 Turnover Growth of 3%-5%

29 avr. 2026, 06:01 UTC

Résultats

GSK PLC Backs 2026 View

29 avr. 2026, 06:00 UTC

Résultats

GSK PLC 1Q EPS 42.6p

29 avr. 2026, 06:00 UTC

Résultats

GSK PLC 1Q Turnover GBP7.63B

29 avr. 2026, 06:00 UTC

Résultats

GSK PLC 1Q Pretax Pft GBP2.14B

29 avr. 2026, 06:00 UTC

Résultats

GSK PLC 1Q Oper Pft GBP2.29B

29 avr. 2026, 06:00 UTC

Résultats

GSK PLC 1Q Net Pft GBP1.74B

15 avr. 2026, 06:12 UTC

Acquisitions, Fusions, Rachats

GSK Completes Acquisition of 35Pharma

10 avr. 2026, 10:43 UTC

Market Talk

GSK Could Report Weak General Medicines Results -- Market Talk

GlaxoSmithKline PLC prévision

Objectif de Prix

By TipRanks

10.68% hausse

Prévisions sur 12 Mois

Moyen 2,082.36 GBX  10.68%

Haut 2,630 GBX

Bas 1,700 GBX

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

14 ratings

4

Achat

7

Maintien

3

Vente

Sentiment

By Acuity

121 / 344Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
help-icon Live chat